DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SAI LIFE SCIENCES LIMITED (SAILIFE) share price today?

SAI LIFE SCIENCES LIMITED (SAILIFE) is trading at ₹1,272 on the NSE, down 1.77% on the day. Source: DocStoX.

What is the PE ratio of SAI LIFE SCIENCES LIMITED?

SAI LIFE SCIENCES LIMITED has a price-to-earnings (PE) ratio of 77.2 in the Healthcare sector.

What is the market capitalisation of SAI LIFE SCIENCES LIMITED?

SAI LIFE SCIENCES LIMITED has a market capitalisation of approximately ₹26,908 crore.

SAI LIFE SCIENCES LIMITED

SAILIFE·NSE·Healthcare

₹1,272.00▼ -22.90 (-1.77%)

Healthcare · Pharmaceuticals

Revenue compounding 22% a year

NIFTY 500NIFTY SMALLCAP 250

Day₹1265.20

₹1294.00

52W₹779

₹130095%

Open

₹1294.00

High

₹1294.00

Low

₹1265.20

Prev Close

₹1294.90

Volume

2.01L

VWAP

₹1272.18

Snapshot

Key fundamentals

Market Cap

₹26,908 Cr

P/E Ratio

77.18Expensive

P/B Ratio

10.57

EPS

₹16.48

Book Value

₹117.00

ROE

15.40%Strong

ROCE

20.00%Efficient

Dividend Yield

0.00%

Debt / Equity

0.12Low

Face Value

₹1.00

52W High

₹1300.00

52W Low

₹778.50

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹154

▼ 87.9%downside

Trading at ₹1,272 — 88% above our estimate

BearFair valueBull

₹131₹154₹208

/100

Business quality — Solid

Growth 93Profitability 65Efficiency 30Valuation 47

Plain English

Our view

Revenue compounding 22% a year
Low debt relative to equity
Expensive — trades at 77× earnings

Strengths

Low debt relative to equity
Capital is working hard (ROCE 20%)
Revenue compounding 22% over 3 years
Profit growing 227% a year

Risks

Expensive — trades at 77× earnings
Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

15% ROE fading to 12% over ~10 yrs, on ₹117 book

₹139

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹208

Analyst target

No analyst coverage

—

Blended fair value₹154

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Capital is working hard (ROCE 20%)
Revenue compounding 22% over 3 years
Profit growing 227% a year

Bear case

Expensive — trades at 77× earnings
Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

77.2Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

15.4%Strong

Above 15% is considered healthy for Indian equities

ROCE

20.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.12Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹26,908 Cr

P/B

10.57

EPS

₹16.48

Div Yield

—

What changed

Recent changes

Foreign investors-0.2% stake last quarter
Domestic institutions+0.1% stake last quarter
Promoters-0.09% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 77.2×

Growth

Strong

+22% rev CAGR

Profitability

Healthy

15.4% ROE

Financial health

Rock solid

D/E 0.12

Momentum

N/A

No technicals

Today

Trading activity

Delivery %50.3%

Turnover₹2559.25L Cr

Trades19,396

VWAP₹1272.18

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+21.7%

+23.6%

10Y

—

Profit

+226.8%

+41.7%

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has delivered good profit growth of 42.2% CAGR over last 5 years

Watch-outs

Cons

Stock is trading at 10.8 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 12.7% over last 3 years.
Working capital days have increased from 51.8 days to 77.6 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters trimmed their stake by 0.09 pts; foreign investors sold 0.23 pts; domestic institutions added 0.13 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

35%

Promoter

Promoters

34.6%-0.09

Public

6.1%+0.18

FII / FPI

21.2%-0.23

DII

31.5%+0.13

Others

6.5%

Total shareholders

1,17,527+2,707 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter34.61%

FII21.17%

DII31.54%

Public6.13%

Others6.55%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1999, Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in pharmaceutical and bio technology industries[1]